Case series:CD19CART cells

2 trials

Sponsors

First people's Hospital of Yunnan Province

Conditions

Refractory Aggressive Non-Hodgkin Lymphoma (NHL)r/r B-ALL

Phase 1

Clinical Study on the Safety and Efficacy of CD19CART Cell Therapy for Refractory B-Cell Leukemia

Active, not recruitingChiCTR1800017634

First people's Hospital of Yunnan Provincer/r B-ALL

Start: 2018-08-08Updated: 2019-04-23

CD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non - Hodgkin's lymphoma

Active, not recruitingChiCTR1800017636

First people's Hospital of Yunnan ProvinceRefractory Aggressive Non-Hodgkin Lymphoma (NHL)

Start: 2018-08-08Updated: 2019-04-23